Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Table 1 List of clinical trials included in the analysis

Study	Phase	Histology	Masking	No. patients	Treatment arms
CA209-067 [8]	3	Melanoma	Double-blind	945	Nivolumab + Ipilimumab vs Nivolumab vs Ipilimumab*
CA209-227 [10]	3	Nonsmall cell lung cancer (NSCLC)	Open-label	1189	Nivolumab + Ipilimumab vs chemotherapy vs Nivolumab*
IFCT-1501 MAPS2 [11]	2	Mesothelioma	Open-label	108	Nivolumab + Ipilimumab vs nivolumab
Alliance A091401 [12]	2	Sarcoma	Open-label	85	Nivolumab + Ipilimumab vs nivolumab*
CA209-032 [13]	1/2	Small cell lung cancer (SCLC)	Open-label	196	Nivolumab + Ipilimumab and Nivolumab**
CA209-032 [14]	1/2	Gastric	Open-label	108	Nivolumab + Ipilimumab and Nivolumab**
CA209-032 [15]	1/2	Bladder	Open-label	196	Nivolumab + Ipilimumab vs nivolumab

ISSN: 1479-5876